Are you over 18 and want to see adult content?
More Annotations
A complete backup of https://westwoodlabs.de
Are you over 18 and want to see adult content?
A complete backup of https://zekitchengalerie.fr
Are you over 18 and want to see adult content?
A complete backup of https://jfcsboston.org
Are you over 18 and want to see adult content?
A complete backup of https://jobscout24.ch
Are you over 18 and want to see adult content?
A complete backup of https://wolf.org
Are you over 18 and want to see adult content?
A complete backup of https://ona-znaet.ru
Are you over 18 and want to see adult content?
A complete backup of https://kaiserthesage.com
Are you over 18 and want to see adult content?
A complete backup of https://ajax1.nl
Are you over 18 and want to see adult content?
A complete backup of https://augmentinpills.com
Are you over 18 and want to see adult content?
A complete backup of https://thestore.com
Are you over 18 and want to see adult content?
A complete backup of https://sustainnatural.com
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of https://bund-rvso.de
Are you over 18 and want to see adult content?
A complete backup of https://agid.gov.it
Are you over 18 and want to see adult content?
A complete backup of https://tsplayground.com
Are you over 18 and want to see adult content?
A complete backup of https://lifelinescreening.com
Are you over 18 and want to see adult content?
A complete backup of https://accountancy.global
Are you over 18 and want to see adult content?
A complete backup of https://essaygator.com
Are you over 18 and want to see adult content?
A complete backup of https://slowfood.org.uk
Are you over 18 and want to see adult content?
A complete backup of https://letsflycheaper.com
Are you over 18 and want to see adult content?
A complete backup of https://checko.nl
Are you over 18 and want to see adult content?
A complete backup of https://mailcleaner.org
Are you over 18 and want to see adult content?
A complete backup of https://noharserymerva.tk
Are you over 18 and want to see adult content?
A complete backup of https://handyhuellen.de
Are you over 18 and want to see adult content?
Text
patients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COMREIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure. LEADERSHIP - RELIEVANT Tyler Binney joined Relievant as President and CEO in April 2021. Prior to joining Relievant, Tyler served as President & General Manager of Interventional Urology at Teleflex and as Vice President of Sales for NeoTract, Inc. (acquired by Teleflex in 2017). Prior to his tenure at NeoTract, Tyler served in multiple leadership roles in sales INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.SMART TRIAL
Patients treated with Intracept for chronic vertebrogenic low back pain exhibited sustained clinical benefits in ODI and VAS and maintained high responder rates at 24 months following treatment. Intracept is a durable, minimally invasive treatment for the relief of chronic vertebrogenic low back pain. 1. VERTEBROGENIC PROCEDURE SPINEU Indications, Contraindications and Risks. The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2021 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C-codes, when billing for procedures.INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
HOME - RELIEVANTINTRACEPT® PROCEDURECLINICAL EVIDENCEREIMBURSEMENTABOUT USVERTEBROGENIC PAIN We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices. 1 While the majority ofpatients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COMREIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure. LEADERSHIP - RELIEVANT Tyler Binney joined Relievant as President and CEO in April 2021. Prior to joining Relievant, Tyler served as President & General Manager of Interventional Urology at Teleflex and as Vice President of Sales for NeoTract, Inc. (acquired by Teleflex in 2017). Prior to his tenure at NeoTract, Tyler served in multiple leadership roles in sales INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.SMART TRIAL
Patients treated with Intracept for chronic vertebrogenic low back pain exhibited sustained clinical benefits in ODI and VAS and maintained high responder rates at 24 months following treatment. Intracept is a durable, minimally invasive treatment for the relief of chronic vertebrogenic low back pain. 1. VERTEBROGENIC PROCEDURE SPINEU Indications, Contraindications and Risks. The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2021 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C-codes, when billing for procedures.INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play. VERTEBROGENIC PROCEDURE SPINEU Indications, Contraindications and Risks. The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is also RELIEVANT MEDSYSTEMS LAUNCHES INTRACEPT.COM PATIENT About Relievant Medsystems Relievant Medsystems is a privately-held medical device company that is transforming the treatment of Chronic Low Back Pain (CLBP) with the Intracept Procedure – a novel, clinically-proven and commercially-available treatment designed to improve the quality of life for the millions of patients suffering from CLBP from degenerative disk disease withCAREERS - RELIEVANT
Careers. At Relievant, we are transforming the lives of people who suffer from chronic low back pain through sound science, innovative procedures and robust clinical research. Our success depends on recruiting and retaining the most talented people and providing them with an environment to thrive and make a real impact. RELIEVANT MEDSYSTEMS NAMES TYLER BINNEY PRESIDENT AND CEO Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Tyler Binney as President and Chief Executive Officer. Mr. Binney will also join Relievant’s Board of Directors. Arthur Taylor, who previously held the CEO position on an interimbasis
VERTEBROGENIC PAIN
Collectively, these findings validate vertebral endplates as a significant source of chronic low back pain in patients with Type 1 or Type 2 modic changes, also referred to as vertebrogenic pain, and this pain is transmitted via the basivertebral nerve. Antonacci MD, Mody DR, Heggeness MH. Innervation of the human vertebral body: ahistologic
INTRACEPT - RELIEVANT Once your physician has determined that the Intracept Procedure is the best treatment to address your chronic low back pain, obtaining prior authorization and approvalBOARD OF DIRECTORS
Ross Jaffe, MD is an experienced healthcare venture capitalist with particular expertise in medical technology. Dr. Jaffe is one of the founding Managing Directors of Versant Ventures, a healthcare-focused venture capital firm, where for the last twenty years he has focused primarily on early-stage medical device companies. RELIEVANT ANNOUNCES PUBLICATION OF LEVEL L INTRACEPT STUDY Relievant Medsystems, a privately-held medical device company focused on transforming the treatment of Chronic Low Back Pain (CLBP), today announced the publication of the Level I INTRACEPT Study results in The Spine Journal. The INTRACEPT Study is a Level I, randomized, multi-center trial comparing the Intracept Procedure to non-surgical standard care. Based on the results of a RELIEVANT ANNOUNCES PUBLICATION OF SMART TRIAL 24-MONTH Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced the publication of 24-month results from the SMART trial in the International Journal of Spine Surgery. A total of 106 of the 128 treatment arm patients in the SMART trial completed 24-month follow up. Data at 3 months and 12 months from HOME - RELIEVANTINTRACEPT® PROCEDURECLINICAL EVIDENCEREIMBURSEMENTABOUT USVERTEBROGENIC PAIN We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices. 1 While the majority ofpatients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COM INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.REIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure.CAREERS - RELIEVANT
Careers. At Relievant, we are transforming the lives of people who suffer from chronic low back pain through sound science, innovative procedures and robust clinical research. Our success depends on recruiting and retaining the most talented people and providing them with an environment to thrive and make a real impact. REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2020 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C codes, when billing for procedures. RELIEVANT ANNOUNCES PUBLICATION OF 5-YEAR DATA Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intraceptprocedure.
INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2021 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C-codes, when billing for procedures. HOME - RELIEVANTINTRACEPT® PROCEDURECLINICAL EVIDENCEREIMBURSEMENTABOUT USVERTEBROGENIC PAIN We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices. 1 While the majority ofpatients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COM INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.REIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure.CAREERS - RELIEVANT
Careers. At Relievant, we are transforming the lives of people who suffer from chronic low back pain through sound science, innovative procedures and robust clinical research. Our success depends on recruiting and retaining the most talented people and providing them with an environment to thrive and make a real impact. REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2020 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C codes, when billing for procedures. RELIEVANT ANNOUNCES PUBLICATION OF 5-YEAR DATA Relievant Medsystems, a privately-held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), today announced European Spine Journal publication of long-term data from the Level I SMART trial showing durability of improvements in pain and function beyond 5 years for patients treated with the Intraceptprocedure.
INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2021 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C-codes, when billing for procedures.REIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure. LEADERSHIP - RELIEVANT Brian joined Relievant in July 2012 and serves as Vice President, Research & Development and Operations. Prior to joining Relievant, Brian was the Site Lead for the Interventional Spine business unit within Medtronic’s Restorative Therapies Group.CLINICAL EVIDENCE
Level l Clinical Evidence. The Intracept Procedure is supported by two Level l randomized clinical trials. Intracept has demonstrated statistical significance compared to both standard care and sham, consistent improvement in both pain and function across both trials, and durable results beyond five years post-procedure. RELIEVANT MEDSYSTEMS NAMES TYLER BINNEY PRESIDENT AND CEO Relievant Medsystems, a privately held medical device company transforming the treatment of Chronic Low Back Pain (CLBP), announced today the appointment of Tyler Binney as President and Chief Executive Officer. Mr. Binney will also join Relievant’s Board of Directors. Arthur Taylor, who previously held the CEO position on an interimbasis
VERTEBROGENIC PROCEDURE SPINEU Indications, Contraindications and Risks. The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is alsoSMART TRIAL
Patients treated with Intracept for chronic vertebrogenic low back pain exhibited sustained clinical benefits in ODI and VAS and maintained high responder rates at 24 months following treatment. Intracept is a durable, minimally invasive treatment for the relief of chronic vertebrogenic low back pain. 1. INTRACEPT - RELIEVANT Once your physician has determined that the Intracept Procedure is the best treatment to address your chronic low back pain, obtaining prior authorization and approvalVERTEBROGENIC PAIN
Collectively, these findings validate vertebral endplates as a significant source of chronic low back pain in patients with Type 1 or Type 2 modic changes, also referred to as vertebrogenic pain, and this pain is transmitted via the basivertebral nerve. Antonacci MD, Mody DR, Heggeness MH. Innervation of the human vertebral body: ahistologic
BOARD OF DIRECTORS
Ross Jaffe, MD is an experienced healthcare venture capitalist with particular expertise in medical technology. Dr. Jaffe is one of the founding Managing Directors of Versant Ventures, a healthcare-focused venture capital firm, where for the last twenty years he has focused primarily on early-stage medical device companies. RELIEVANT ANNOUNCES PUBLICATION OF LEVEL L INTRACEPT STUDY Relievant Medsystems, a privately-held medical device company focused on transforming the treatment of Chronic Low Back Pain (CLBP), today announced the publication of the Level I INTRACEPT Study results in The Spine Journal. The INTRACEPT Study is a Level I, randomized, multi-center trial comparing the Intracept Procedure to non-surgical standard care. Based on the results of a HOME - RELIEVANTINTRACEPT® PROCEDURECLINICAL EVIDENCEREIMBURSEMENTABOUT USVERTEBROGENIC PAIN We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices. 1 While the majority ofpatients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COMREIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure. LEADERSHIP - RELIEVANT Tyler Binney joined Relievant as President and CEO in April 2021. Prior to joining Relievant, Tyler served as President & General Manager of Interventional Urology at Teleflex and as Vice President of Sales for NeoTract, Inc. (acquired by Teleflex in 2017). Prior to his tenure at NeoTract, Tyler served in multiple leadership roles in sales INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
VERTEBROGENIC PAIN
Collectively, these findings validate vertebral endplates as a significant source of chronic low back pain in patients with Type 1 or Type 2 modic changes, also referred to as vertebrogenic pain, and this pain is transmitted via the basivertebral nerve. Antonacci MD, Mody DR, Heggeness MH. Innervation of the human vertebral body: ahistologic
REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2020 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C codes, when billing for procedures. RELIEVANT ANNOUNCES PUBLICATION OF SMART TRIAL 24-MONTH Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced the publication of 24-month results from the SMART trial in the International Journal of Spine Surgery. A total of 106 of the 128 treatment arm patients in the SMART trial completed 24-month follow up. Data at 3 months and 12 months from HOME - RELIEVANTINTRACEPT® PROCEDURECLINICAL EVIDENCEREIMBURSEMENTABOUT USVERTEBROGENIC PAIN We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices. 1 While the majority ofpatients with
ABOUT US - RELIEVANT Our Story Relievant Medsystems is a privately held medical device company with headquarters in Minneapolis, MN. Based on two decades of research, we developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. After a successful Pilot Study,1 we sponsored the SMART Trial — the medical device PROCEDURE - RELIEVANTSEE MORE ON RELIEVANT.COMREIMBURSEMENT
Relievant is committed to providing patients, physicians and facilities with resources to assist in the reimbursement process and to gain patient access for treatment with the Intracept Procedure. Relievant has a dedicated team of professionals to assist in the prior authorization of the Intracept Procedure. LEADERSHIP - RELIEVANT Tyler Binney joined Relievant as President and CEO in April 2021. Prior to joining Relievant, Tyler served as President & General Manager of Interventional Urology at Teleflex and as Vice President of Sales for NeoTract, Inc. (acquired by Teleflex in 2017). Prior to his tenure at NeoTract, Tyler served in multiple leadership roles in sales INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.INTRACEPT STUDY
Study Design. Prospective, randomized, multi-center. 20 US sites. 104 Patients; Randomized to Intracept (51) or standard care (53) Patients were evaluated at baseline and at 3, 6, 9, and 12 months post-treatment. Skeletally mature patients with low back pain ≥ 6 months who had not responded to at least 6 months of conservativecare.
VERTEBROGENIC PAIN
Collectively, these findings validate vertebral endplates as a significant source of chronic low back pain in patients with Type 1 or Type 2 modic changes, also referred to as vertebrogenic pain, and this pain is transmitted via the basivertebral nerve. Antonacci MD, Mody DR, Heggeness MH. Innervation of the human vertebral body: ahistologic
REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2020 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C codes, when billing for procedures. RELIEVANT ANNOUNCES PUBLICATION OF SMART TRIAL 24-MONTH Relievant Medsystems, a privately-held medical device company developing minimally-invasive solutions for chronic low back pain (CLBP), today announced the publication of 24-month results from the SMART trial in the International Journal of Spine Surgery. A total of 106 of the 128 treatment arm patients in the SMART trial completed 24-month follow up. Data at 3 months and 12 months from INTRACEPT® PROCEDURE The Intracept Procedure targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain. !Relievant_Intracept_Physician_TF921_024_High from Relievant Medsystems on Vimeo. Play.PATIENT STORIES
Kourtney’s Story. “My best friend said to me I have not heard you talk about your back in so long.”. MKT 0220 Rev A_Patient Testimonial_Dr Ekstrom and Karen_HD 1080p from Relievant Medsystems on Vimeo. Play. Pause. Play. LIVE. 0. 00:00.CLINICAL EVIDENCE
Level l Clinical Evidence. The Intracept Procedure is supported by two Level l randomized clinical trials. Intracept has demonstrated statistical significance compared to both standard care and sham, consistent improvement in both pain and function across both trials, and durable results beyond five years post-procedure. VERTEBROGENIC PROCEDURE SPINEU Indications, Contraindications and Risks. The Intracept Intraosseous Nerve Ablation System is intended to be used in conjunction with radiofrequency (RF) generators for the ablation of basivertebral nerves of the L3 through S1 vertebrae for the relief of chronic low back pain of at least six months duration that has not responded to at least six months of conservative care, and is alsoCAREERS - RELIEVANT
Careers. At Relievant, we are transforming the lives of people who suffer from chronic low back pain through sound science, innovative procedures and robust clinical research. Our success depends on recruiting and retaining the most talented people and providing them with an environment to thrive and make a real impact.NEWS AND EVENTS
July 21, 2016 — Redwood City, CA. Relievant Medsystems, Inc., a privately held medical device company pioneering the therapy of nerve ablation within vertebral bodies for the treatment of chronic low back pain, announced today that it received U.S. Food and Drug Administration (FDA) 510 (k) clearance for the INTRACEPT®Intraosseous Nerve
SMART TRIAL
Patients treated with Intracept for chronic vertebrogenic low back pain exhibited sustained clinical benefits in ODI and VAS and maintained high responder rates at 24 months following treatment. Intracept is a durable, minimally invasive treatment for the relief of chronic vertebrogenic low back pain. 1. REIMBURSEMENT INFORMATION FOR THE INTRACEPT PROCEDURE Hospital Outpatient Coding and 2021 Medicare Payment Hospital Outpatient Departments (HOPDs) also report CPT codes, and in some instances, HCPCS C-codes, when billing for procedures.BOARD OF DIRECTORS
Ross Jaffe, MD is an experienced healthcare venture capitalist with particular expertise in medical technology. Dr. Jaffe is one of the founding Managing Directors of Versant Ventures, a healthcare-focused venture capital firm, where for the last twenty years he has focused primarily on early-stage medical device companies.SMART 5 YEAR
Study Design. Prospective five year follow-up of the SMART US treatment arm patients 1, 2, 3. All 13 US treating sites participated. Retention rate of 85% per protocol treatment arm population (n=100) (PP = Per Protocol) Mean follow-up of 6.4 years (range 5.4 to 7.8 years posttreatment)Relievant menu
* Intracept® Procedure* Overview
* Vertebrogenic Pain* Procedure
* Patient Stories
* Clinical Evidence
* Overview
* SMART Trial
* INTRACEPT Study
* Reimbursement
* About Us
* Our Story
* Leadership
* Board of Directors* News and Events
* Careers
* Contact
Search for: Search
Previous
*
Level l INTRACEPT Study DEMONSTRATES HIGHLY SIGNIFICANT RESULTS*
The Role of
VERTEBRAL ENDPLATES
in Chronic Vertebrogenic Low Back Pain*
THE INTRACEPT PROCEDURE for the Relief of Chronic Vertebrogenic Low Back Pain*
Level l SMART Trial DemonstratesDURABLE RELIEF
Next
* 1
* 2
* 3
* 4
We are committed to providing new solutions to the millions of patients suffering from chronic low back pain (CLBP). At any given time, low back pain impacts nearly 30% of the US population, leading to 52 million annual visits to hospitals, emergency departments, outpatient clinics, and physician offices.1 While the majority of patients with low back pain improve, up to 15% of these patients experience chronic low back pain.2 Today, patients with CLBP are treated with conservative treatments such as physical therapy or injections, medications such as opioids, or potentially surgical options including spinal fusion or total disc replacement. Unfortunately, conservative treatments do not provide adequate relief for the majority of patients and only a small percentage are surgically eligible. The focus has traditionally been on the intervertebral discs as the primary source of CLBP, known as discogenic pain. Research published over the past 20 years has concluded that vertebral body endplates are a significant source of CLBP. This pain is referred to as vertebrogenic pain and is transmitted via the basivertebral nerve, which is found within the vertebral body. Based on this research, Relievant developed the Intracept Procedure — a minimally invasive procedure that targets the basivertebral nerve for the relief of chronic vertebrogenic low back pain.* Intracept is supported with Level I clinical evidence and is commercially available in the United States. > “The Intracept Procedure is a new, minimally invasive option to > treat chronic vertebrogenic low back pain. The procedure has been > proven to be safe and effective in clinical trials, and is much less > invasive than typical surgical options to treat vertebrogenic> pain.”
>
> JEFFREY FISCHGRUND, MD, CHAIRMAN, DEPARTMENT OF ORTHOPEDICS, > BEAUMONT HOSPITAL, ROYAL OAK AND PRINCIPAL INVESTIGATOR OF THE SMART> TRIAL
* Burden of Musculoskeletal Disease in the United States, Third Edition – Copyright © 2014–2015 by the United States Bone andJoint Initiative
* Baker RM. Commentary on Classification of patients with incident non-specific low back pain: implications for research. The Spine Journal 16 (2016) 577–578 * Indications and RisksRelievant
* Intracept® Procedure* Overview
* Vertebrogenic Pain* Procedure
* Patient Stories
* Clinical Evidence
* Overview
* SMART Trial
* INTRACEPT Study
* Reimbursement
* About Us
* Leadership
* Board of Directors* News and Events
* Careers
* Contact
* RELIEVANT MEDSYSTEMS, INC. * CORPORATE HEADQUARTERS * 8500 Normandale Lake Blvd, Suite 2150 * Minneapolis, MN 55437-3833* 650-368-1000
* DEVELOPMENT AND OPERATIONS * 1230 Midas Way, Suite 200 * Sunnyvale, CA 94085* Terms of Use
* Privacy Policy
* MKT 0009 Rev. P
* © 2020 Relievant Medsystems, Inc. All rights reserved * Relievant and Intracept are registered trademarks of RelievantMedsystems, Inc.
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0